New England Journal of Medicine

Asthma biologic may reduce oral steroid useA new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.
Small Doses: The Weekly News You Need to Know
Small Doses: The Weekly News You Need to KnowSmall doses is a weekly slideshow of the news you may have missed, made just for you and your busy lifestyle.
QD Fluticasone-Vilanterol combo reduces COPD exacerbationsIn patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events
DRCR.net retinal treatment results take center stage in 2015Studies of the efficacy of anti-vascular endothelial growth factor (VEGF), gene therapies, and slow-release drug delivery systems took center stage among treatments for retinal disorders in 2015. In addition to studies already under way, others are about to begin.
Comparing anti-VEGFs for DMEIn a 1-year comparison of intravitreous aflibercept, bevacizumab and ranibizumab therapy for centre-involved DME, aflibercept was more effective at improving vision among patients who started treatment at lower levels of visual acuity.
Global payments show promise of reining in healthcare costsStudy finds slower spending increases, better outcomes compared with traditional payment methods
ACA helping more adults to obtain healthcare insurance, surveys findGains occur across age groups but are greater in states expanding Medicaid coverage
Diabetes-related complications show dramatic reductionThe nation’s decades-long focus on treating the disease and its consequences appears to be yielding results
CDC report raises alarm about hospital infectionsEveryday, approximately one in 25 U.S. patients contracts at least one infection during the course of their hospital care, according to new data from the Centers for Disease Control and Prevention.
How to manage skin abscesses with MRSAMore than a decade after the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), physicians are still trying to figure out how to diagnose, treat, and prevent this virulent form of staph infection, which is immune to many antibiotics.